低剂量BCG疫苗保护放牧牛抵抗自然感染牛结核
在新西兰对超过800头1-2岁放牧牛进行多年随机试验,分别注射3×10^5 BCG或作为未接种对照,屠宰后检查M. bovis培养阳性结核病变。接种组520头中2例(0.38%)有病变,对照组297头中8例(2.69%),疫苗效力85.7%(对屠宰可检测结核),暴露时间校正后为86.7%。接种后超过7个月,BCG接种未显著影响牛对生前皮肤或血液诊断试验的反应率。
要点
- 接种3×10^5 BCG的520头牛中2头(0.38%)出现屠宰可检测结核病变,未接种297头中8头(2.69%)。
- 疫苗对屠宰可检测结核的效力为85.7%,暴露时间校正后为86.7%。
- 接种后超过7个月,BCG接种未显著影响牛对生前皮肤或血液诊断试验的反应率。
核心结论
- 低剂量BCG接种对放牧牛自然感染牛结核具有统计学显著保护作用,疫苗效力85.7%(暴露时间校正后86.7%)。
- 使用降低但仍有效的BCG剂量可提高该疫苗在牛结核控制规划中的成本效益。
研究设计与样本
- 在新西兰开展大规模多年入组研究,涉及超过800头1-2岁放牧牛,随机分为接种组(注射3×10^5 BCG)和未接种对照组。
- 牛在田间暴露最多3.7年后屠宰,进行标准屠宰场尸检以检测M. bovis培养阳性结核病变;约半数牛的淋巴结样本进一步检查以识别无病变感染。
主要发现
- 研究地点农场牛群总体结核患病率低(每年<4%)。
- 接种组520头中2头(0.38%)有病变,未接种组297头中8头(2.69%)有病变。
- 疫苗对屠宰可检测结核的效力为85.7%,暴露时间校正后为86.7%。
- 接种后超过7个月,BCG接种未显著影响牛对生前皮肤或血液诊断试验的反应率。
关键数值与推荐
- 接种剂量:3×10^5 BCG via injection,低于此前任何牛只自然攻击试验中的剂量。
临床怎么用
- 低剂量BCG接种可为放牧牛提供针对自然感染牛结核的显著保护,且不显著干扰接种后超过7个月的生前皮肤或血液诊断试验反应率。
- 采用降低但仍有效的BCG剂量可提高牛结核控制规划中使用该疫苗的成本效益。
局限性
- 原文未述局限性
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
Vaccination of cattle with Mycobacterium bovis BCG has been shown to protect against infection with virulent strains of M. bovis, and against resultant bovine tuberculosis (TB). Here we report on a large-scale trial in New Zealand where free-ranging cattle were vaccinated with 3 x 105 BCG via injection, a lower dose than any previously trialed in cattle against exposure to a natural force of M. bovis infection. In a multi-year enrolment study involving >800 animals, three cohorts of 1-2 year old cattle were randomised to receive vaccine or to serve as non-vaccinated controls. Cattle were slaughtered and subject to standard abattoir post mortem examination for M. bovis culture-positive TB lesions after up to 3.7 years of in-field exposure; additionally, lymph node samples from approximately half of the cattle were examined further to identify infection in the absence of lesions. Overall TB prevalence, as identified by gross lesions detected at slaughter, was low among farmed cattle at the study site (<4% annually). There were two lesioned cases among 520 vaccinated trial cattle (0.38%) compared to eight among 297 non-vaccinated trial cattle (2.69%). Trial vaccine efficacy was 85.7% against abattoir-detectable TB (statistically significant protection), and 86.7% when adjusted for duration of exposure. BCG vaccination did not significantly affect the response rates of cattle to ante mortem skin- or blood-tests in diagnostic tests conducted >7 months post-vaccination. Use of a reduced, yet effective, dose of BCG would increase the cost effectiveness of using this vaccine in a bovine TB control programme.
引用
- Nugent G, Yockney IJ, Cross ML, et al. Low-dose BCG vaccination protects free-ranging cattle against naturally-acquired bovine tuberculosis. Vaccine. 2018. PMID: 30327211. doi:10.1016/j.vaccine.2018.10.025
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。